← FDA DRUG APPROVALS

FDA ANDA · ANDA078728

GLIPIZIDE AND METFORMIN HCL

Sponsor: HERITAGE

APPLICATION
ANDA078728
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-23
LATEST ACTION
2017-04-05
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 2.5MG, METFORMIN HYDROCHLORIDE 250MG · TABLET · ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 2.5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL

Approval history

2017-04-05Labeling · Supplement 5 · standardAP
2017-04-04Labeling · Supplement 2 · standardAP
2010-06-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →